SCM
PCSA icon

Solas Capital Management’s Processa Pharmaceuticals PCSA Stock Holding History

Solas Capital Management’s Portfolio PCSA Stock Details PCSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-46
Closed -$69K – 24
2022
Q1 		$69K Sell
46
-346
-88% -$659K 0.04% 23
2021
Q4 		$961K Hold
392
– – 0.69% 24
2021
Q3 		$1.68M Hold
392
– – 1.17% 23
2021
Q2 		$1.61M Sell
392
-8
-2% -$30.9K 1.13% 23
2021
Q1 		$2.18M Sell
400
-500
-56% -$2.33M 1.83% 20
2020
Q4 		$2.97M Buy
+900
New +$2.5M 2.26% 20

Other funds holding PCSA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCA
Verdence Capital Advisors Hunt Valley, Maryland $1.72B AUM 24.88% 1-Year Est. Return
CBA
Coastal Bridge Advisors Westport, Connecticut $1.41B AUM 24.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $40.4B AUM 21.2% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Solas Capital Management's PCSA Position: Q2 2022 in Review

Solas Capital Management sold out of Processa Pharmaceuticals (PCSA) in Q2 2022, closing a stake of 46 shares — an estimated $69K sold.

Solas Capital Management first reported a position in PCSA in Q4 2020 and held it in 6 quarters. The position peaked at $2.97M in Q4 2020. 18 funds tracked by Wall St. Rank hold PCSA as of Q2 2022.

  • Solas Capital Management reported no remaining Processa Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Solas Capital Management sold 46 Processa Pharmaceuticals shares in Q2 2022, an estimated $69K.
  • Solas Capital Management first reported a position in Processa Pharmaceuticals in Q4 2020 and held it in 6 quarters.
  • Solas Capital Management's Processa Pharmaceuticals position peaked at $2.97M in Q4 2020.
  • 18 funds tracked by Wall St. Rank held Processa Pharmaceuticals as of Q2 2022.

Based on Solas Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.